Xintela AB (publ) (STO:XINT)
0.2850
0.00 (0.00%)
Apr 10, 2026, 1:10 PM CET
Xintela AB Revenue
In the year 2025, Xintela AB had annual revenue of 2.28M SEK, down -45.86%. Xintela AB had revenue of 415.00K in the quarter ending December 31, 2025, a decrease of -61.93%.
Revenue
2.28M
Revenue Growth
-45.86%
P/S Ratio
107.56
Revenue / Employee
175.54K
Employees
13
Market Cap
245.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.28M | -1.93M | -45.86% |
| Dec 31, 2024 | 4.22M | 4.14M | 5,303.85% |
| Dec 31, 2023 | 78.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sprint Bioscience AB | 167.17M |
| Xbrane Biopharma AB | 152.35M |
| Bio-Works Technologies AB | 63.11M |
| Intervacc AB | 20.09M |
| Elicera Therapeutics AB | 10.86M |
| Diamyd Medical AB | 362.00K |
| Mendus AB | -1.44M |